Related references
Note: Only part of the references are listed.Clinical, Immunological, and Genetic Features in Patients with Activated PI3Kδ Syndrome (APDS): a Systematic Review
Mahnaz Jamee et al.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2020)
PDK1 Mediates NOTCH1-Mutated Head and Neck Squamous Carcinoma Vulnerability to Therapeutic PI3K/mTOR Inhibition
Vaishnavi Sambandam et al.
CLINICAL CANCER RESEARCH (2019)
New insights into a spectrum of developmental malformations related to mTOR dysregulations: challenges and perspectives
A. Muhlebner et al.
JOURNAL OF ANATOMY (2019)
Overgrowth syndromes - clinical and molecular aspects and tumour risk
Frederic Brioude et al.
NATURE REVIEWS ENDOCRINOLOGY (2019)
First evidence of a therapeutic effect of miransertib in a teenager with Proteus syndrome and ovarian carcinoma
Chiara Leoni et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART A (2019)
Targeting PI3K signaling in cancer: Challenges and advances
Maria Chiara De Santis et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2019)
Duvelisib: a new phosphoinositide-3-kinase inhibitor in chronic lymphocytic leukemia
Anna M. Frustaci et al.
FUTURE ONCOLOGY (2019)
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
Fabrice Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases
Franziska Maria Ippen et al.
NEURO-ONCOLOGY (2019)
The PTEN-PI3K Axis in Cancer
Antonella Papa et al.
BIOMOLECULES (2019)
MicroRNA-21-5p targeting PDCD4 suppresses apoptosis via regulating the PI3K/AKT/FOXO1 signaling pathway in tongue squamous cell carcinoma
Changfu Liu et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2019)
The other mTOR complex: New insights into mTORC2 immunobiology and their implications
Helong Dai et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2019)
Targeting the Mammalian Target of Rapamycin for Epileptic Encephalopathies and Malformations of Cortical Development
Anna Jeong et al.
JOURNAL OF CHILD NEUROLOGY (2018)
Comparative Effects of Topical 0.2% Sirolimus for Angiofibromas in Adults and Pediatric Patients with Tuberous Sclerosis Complex
Young In Lee et al.
DERMATOLOGY (2018)
65 YEARS OF THE DOUBLE HELIX One gene, many endocrine and metabolic syndromes: PTEN-opathies and precision medicine
Lamis Yehia et al.
ENDOCRINE-RELATED CANCER (2018)
Everolimus dosing recommendations for tuberous sclerosis complex-associated refractory seizures
David N. Franz et al.
EPILEPSIA (2018)
Strategies for Enhancing the Permeation of CNS-Active Drugs through the Blood-Brain Barrier: A Review
Isra' Zeiadeh et al.
MOLECULES (2018)
Review: Mechanistic target of rapamycin (mTOR) pathway, focal cortical dysplasia and epilepsy
E. Marsan et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2018)
Efficacy and Safety of Topical Rapamycin in Patients With Facial Angiofibromas Secondary to Tuberous Sclerosis Complex The TREATMENT Randomized Clinical Trial
Mary Kay Koenig et al.
JAMA DERMATOLOGY (2018)
Activated PI3 Kinase Delta Syndrome: From Genetics to Therapy
David Michalovich et al.
FRONTIERS IN IMMUNOLOGY (2018)
Down-regulation of Rictor enhances cell sensitivity to PI3K inhibitor LY294002 by blocking mTORC2-medicated phosphorylation of Akt/PRAS40 in esophageal squamous cell carcinoma
Guiqin Hou et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
Targeted therapy in patients with PIK3CA-related overgrowth syndrome
Quitterie Venot et al.
NATURE (2018)
The novel, catalytic mTORC1/2 inhibitor PQR620 and the PI3K/mTORC1/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy
Claudia Brandt et al.
NEUROPHARMACOLOGY (2018)
Effect of Buparlisib, a Pan-Class I PI3K Inhibitor, in Refractory Follicular and Poorly Differentiated Thyroid Cancer
Francoise Borson-Chazot et al.
THYROID (2018)
Cancer-Associated PIK3CA Mutations in Overgrowth Disorders
Ralitsa R. Madsen et al.
TRENDS IN MOLECULAR MEDICINE (2018)
Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-y1})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders
Denise Rageot et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
mTOR inhibitor therapy as a disease modifying therapy for tuberous sclerosis complex
David Neal Franz et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART C-SEMINARS IN MEDICAL GENETICS (2018)
A Potent and Selective ULK1 Inhibitor Suppresses Autophagy and Sensitizes Cancer Cells to Nutrient Stress
Katie R. Martin et al.
ISCIENCE (2018)
A RANDOMISED, DOUBLE-BLIND STUDY TO ASSESS THE SAFETY, TOLERABILITY AND PRELIMINARY EFFICACY OF LENIOLISIB (CDZ173) IN PATIENTS WITH PRIMARY SJOGREN'S SYNDROME
T. Doerner et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
New developments in understanding focal cortical malformations
Albert J. Becker et al.
CURRENT OPINION IN NEUROLOGY (2018)
Everolimus in Patients With Advanced Follicular-Derived Thyroid Cancer: Results of a Phase II Clinical Trial
Tatiana C. Schneider et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2017)
Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer
Christophe Massard et al.
EUROPEAN JOURNAL OF CANCER (2017)
Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer
Andrew J. Armstrong et al.
EUROPEAN JOURNAL OF CANCER (2017)
Molecular diagnosis of PIK3CA-related overgrowth spectrum (PROS) in 162 patients and recommendations for genetic testing
Paul Kuentz et al.
GENETICS IN MEDICINE (2017)
Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma
Anas Younes et al.
HAEMATOLOGICA (2017)
MenTORing Immunity: mTOR Signaling in the Development and Function of Tissue-Resident Immune Cells
Russell G. Jones et al.
IMMUNITY (2017)
5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology
Florent Beaufils et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development
Hua-fu Zhao et al.
MOLECULAR CANCER (2017)
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
R. S. Finkel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors
Klemens Hoegenauer et al.
ACS MEDICINAL CHEMISTRY LETTERS (2017)
Deconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention
Thomas Bohnacker et al.
NATURE COMMUNICATIONS (2017)
CC-115, a dual inhibitor of mTOR kinase and DNA-PK, blocks DNA damage repair pathways and selectively inhibits ATM-deficient cell growth in vitro
Toshiya Tsuji et al.
ONCOTARGET (2017)
Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma
Anas Younes et al.
HAEMATOLOGICA (2017)
PI3K Signaling in Tissue Hyper-Proliferation: From Overgrowth Syndromes to Kidney Cysts
Maria Chiara De Santis et al.
CANCERS (2017)
mTOR signaling in immune cells and its implications for cancer immunotherapy
Hu Zeng
CANCER LETTERS (2017)
The PI3K Pathway in Human Disease
David A. Fruman et al.
CELL (2017)
Somatic Mutations in TSC1 and TSC2 Cause Focal Cortical Dysplasia
Jae Seok Lim et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2017)
Mosaic Disorders of the PI3K/PTEN/AKT/TSC/mTORC1 Signaling Pathway
Neera Nathan et al.
DERMATOLOGIC CLINICS (2017)
Familial Cortical Dysplasia Caused by Mutation in the Mammalian Target of Rapamycin Regulator NPRL3
Joe C. Sim et al.
ANNALS OF NEUROLOGY (2016)
TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenstrom's macroglobulinemia
Irene M. Ghobrial et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Nephroblastomatosis or Wilms tumor in a fourth patient with a somatic PIK3CA mutation
Karen W. Gripp et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART A (2016)
Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway & therapeutic strategies
Kim M. Keppler-Noreuil et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART C-SEMINARS IN MEDICAL GENETICS (2016)
Brain somatic mutations in MTOR leading to focal cortical dysplasia
Jae Seok Lim et al.
BMB REPORTS (2016)
Dactolisib (NVP-BEZ235) toxicity in murine brain tumour models
I. A. Netland et al.
BMC CANCER (2016)
A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer
Thomas Powles et al.
EUROPEAN UROLOGY (2016)
Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study
Jacqueline A. French et al.
LANCET (2016)
Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers
Kevin Hudson et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Convulsive seizures from experimental focal cortical dysplasia occur independently of cell misplacement
Lawrence S. Hsieh et al.
NATURE COMMUNICATIONS (2016)
Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy
Klaus Okkenhaug et al.
CANCER DISCOVERY (2016)
Association of MTOR Mutations With Developmental Brain Disorders, Including Megalencephaly, Focal Cortical Dysplasia, and Pigmentary Mosaicism
Ghayda M. Mirzaa et al.
JAMA NEUROLOGY (2016)
Tuberous sclerosis complex
Elizabeth P. Henske et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
PIK3CA-associated developmental disorders exhibit distinct classes of mutations with variable expression and tissue distribution
Ghayda Mirzaa et al.
JCI INSIGHT (2016)
A Phase I Dose-Escalation Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of the Dual mTORC1/mTORC2 Kinase Inhibitor CC-223 in Patients With Advanced Solid Tumors or Multiple Myeloma
Johanna C. Bendell et al.
CANCER (2015)
Pre-clinical evaluation of AZD-2014, a novel mTORC1/2 dual inhibitor, against renal cell carcinoma
Bing Zheng et al.
CANCER LETTERS (2015)
First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014
Bristi Basu et al.
CLINICAL CANCER RESEARCH (2015)
AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules
Sylvie M. Guichard et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Survival benefit and phenotypic improvement by hamartin gene therapy in a tuberous sclerosis mouse brain model
Shilpa Prabhakar et al.
NEUROBIOLOGY OF DISEASE (2015)
Focal dysplasia of the cerebral cortex and infantile spasms associated with somatic 1q21.1-q44 duplication including the AKT3 gene
V. Conti et al.
CLINICAL GENETICS (2015)
Familial cortical dysplasia type IIA caused by a germline mutation in DEPDC5
Thomas Scerri et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2015)
Incidence, prevalence and aetiology of seizures and epilepsy in children
Peter Camfield et al.
EPILEPTIC DISORDERS (2015)
Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum
Kim M. Keppler-Noreuil et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART A (2014)
An mTOR anti-sense oligonucleotide decreases polycystic kidney disease in mice with a targeted mutation in Pkd2
Kameswaran Ravichandran et al.
HUMAN MOLECULAR GENETICS (2014)
Characterization of the Activity of the PI3K/mTOR Inhibitor XL765 (SAR245409) in Tumor Models with Diverse Genetic Alterations Affecting the PI3K Pathway
Peiwen Yu et al.
MOLECULAR CANCER THERAPEUTICS (2014)
PI3K and cancer: lessons, challenges and opportunities
David A. Fruman et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
Ajay K. Gopal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity
Brian C. Grabiner et al.
CANCER DISCOVERY (2014)
Everolimus Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex
Darcy A. Krueger et al.
ANNALS OF NEUROLOGY (2013)
BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models
Ningshu Liu et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Mammalian Target of Rapamycin (mTOR) Pathways in Neurological Diseases
Michael Wong
Biomedical Journal (2013)
mTOR Signaling in Growth Control and Disease
Mathieu Laplante et al.
CELL (2012)
Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models
Jill M. Spoerke et al.
CLINICAL CANCER RESEARCH (2012)
Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA
Marjorie J. Lindhurst et al.
NATURE GENETICS (2012)
Targeted therapy in rare cancers-adopting the orphans
Javier Munoz et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Somatic Activation of AKT3 Causes Hemispheric Developmental Brain Malformations
Annapurna Poduri et al.
NEURON (2012)
Modulators of Sensitivity and Resistance to Inhibition of PI3K Identified in a Pharmacogenomic Screen of the NCI-60 Human Tumor Cell Line Collection
Kevin A. Kwei et al.
PLOS ONE (2012)
Non-canonical functions of the tuberous sclerosis complex-Rheb signalling axis
Nicole A. Neuman et al.
EMBO MOLECULAR MEDICINE (2011)
Rapamycin passes the torch: a new generation of mTOR inhibitors
Don Benjamin et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1)
Laura R. Pearce et al.
BIOCHEMICAL JOURNAL (2010)
Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3′ Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models
Carol O'Brien et al.
CLINICAL CANCER RESEARCH (2010)
Intranasally delivered siRNA targeting PI3K/Akt/mTOR inflammatory pathways protects from aspergillosis
P. Bonifazi et al.
MUCOSAL IMMUNOLOGY (2010)
Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis.
Darcy A. Krueger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Jeffrey A. Engelman
NATURE REVIEWS CANCER (2009)
Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex
Ling-Hui Zeng et al.
ANNALS OF NEUROLOGY (2008)
A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition
Neil E. Torbett et al.
BIOCHEMICAL JOURNAL (2008)
Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis
Dan Ehninger et al.
NATURE MEDICINE (2008)
PI3K pathway alterations in cancer: variations on a theme
T. L. Yuan et al.
ONCOGENE (2008)
Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control
R Loewith et al.
MOLECULAR CELL (2002)
Focal cortical dysplasia: neuropathological subtypes, EEG, neuroimaging and surgical outcome
L. Tassi et al.
BRAIN (2002)
Share Paper
